Search

Your search keyword '"Adotevi, O."' showing total 142 results

Search Constraints

Start Over You searched for: Author "Adotevi, O." Remove constraint Author: "Adotevi, O."
142 results on '"Adotevi, O."'

Search Results

1. KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM

2. LBA6 UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells and epitope spreading in patients with advanced non-small cell lung cancer

3. 180P Recalling pre-existing microbiota-specific T cells to target tumors

4. 203P Early remodeling of systemic antitumor T cell immunity in head and neck cancer patients treated by chemoradiation

7. P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer

8. Valeur pronostique de la lymphopénie T CD4 + dans le cancer du poumon non à petites cellules

10. Les auteurs

11. Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients

12. Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma

13. P1.14-19 Exome Analysis of Patients Treated with Afatinib Reveals Genetic Variations Discriminating Extreme Responders

16. Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)

17. Understanding the anti-tumor T cell responses modulation mediated by chemoradiation to improve immunotherapy efficacy

18. The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small cell lung cancer

19. Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors

22. In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

23. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

24. Presence of naturally occurring anti-telomerase CD4 Th1 immunity in glioblastoma

26. Pre-existing antitumor CD4 Th1 immunity in blood and PD-1/TIM-3+ CD4 T cells predict distinct outcome in lung cancer

28. 1789P - Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients

29. Myeloid-derived suppressor cells are associated with a decrease of tumor antigen-specific Th1 immunity in non-small cell lung cancer

36. 415PD - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors

40. B subunit of shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity

41. Prognostic Value of Angiopoietin-2 for Overall Survival in Patients with Metastatic Colorectal Carcinoma Treated By Chemotherapy and Bevacizumab

45. Immunogenic HLA-B7-restricted peptides of hTRT

48. 660P Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study.

49. c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells

50. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Catalog

Books, media, physical & digital resources